Glatiramer acetate liposomal (Pharmsynthez/Xenetic Biosciences)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameGlatiramer acetate liposomal (Pharmsynthez/Xenetic Biosciences)
Drug Alias NameLiposomal multiple sclerosis vaccine醋酸格拉替雷脂质体 - Pharmsynthez/Xenetic BiosciencesMyeloXen
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunomodulatorsMajor histocompatibility complex II modulators
TargetsMajor histocompatibility complex II
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPharmsynthez
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmsynthezXenetic Biosciences Inc
Active IndicationsN/A
Inactive IndicationsMultiple Sclerosis

Other Information

ATC CodeN/A
Related LinksN/A